3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Neuroendocrine Tumors
3
Gastro-enteropancreatic neuroendocrine tumor
3
Adenoma, Islet Cell
2
Recurrence
1
Pancreatitis
1
Pancreatic Intraductal Neoplasms
1
Meningioma
1
Fistula
1
Duodenal Neoplasms
1
Carcinoid Tumor
1
Acromegaly
1
Interventions
zimberelimab
1
pembrolizumab
1
olaparib
1
lutetium Lu 177 dotatate
1
lanreotide
1
fluorodopa F 18
1
cabozantinib
1
Sunitinib
1
Random Allocation
1
Octreotide
1
Nivolumab
1
Everolimus
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoid Tumor
×
Octreotide
×
1 year
×
Clear all
NCT05477576
2026-03-30
ACTION-1
RayzeBio, Inc.
Phase 3
Recruiting
338 enrolled